| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Bacterial cell wall synthesis enzymes (penicillin-binding proteins). As a penicillin antibiotic, carbenicillin inhibits transpeptidase enzymes involved in bacterial cell wall peptidoglycan synthesis, leading to bacterial cell lysis and death.
|
|---|---|
| ln Vitro |
In vitro, carnacillin sodium exhibits activity against a wide range of bacterial species[1].
Carindacillin sodium is active against a broad spectrum of bacterial species in vitro, effectively inhibiting the growth of both Gram-positive and Gram-negative strains. It is active against susceptible strains of Escherichia coli, Proteus mirabilis, Morganella morganii, Providencia rettgeri, Proteus vulgaris, Pseudomonas, Enterobacter, and Enterococci. |
| ln Vivo |
Carindacillin sodium (po), with PD95s ranging from 30.4 mg/kg to 220.4 mg/kg, protects mice against deadly infections caused by Salmonella choleraesuis, Pasteurella multocida, Proteus vulgaris, Staphylococcus aureus, and Streptococcus pyogenes[1].
Oral administration of Carindacillin sodium protects mice against lethal infections from pathogens like E. coli and S. aureus, with PD₉₅ values ranging from 30.4 to 220.4 mg/kg. It is used clinically for the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria. |
| Enzyme Assay |
Antibacterial susceptibility testing is performed following CLSI guidelines. Minimum inhibitory concentrations (MICs) are determined using broth microdilution or agar dilution methods against a panel of bacterial strains including E. coli, P. mirabilis, Pseudomonas, and Enterococci. The prodrug is also tested for its ability to be hydrolyzed to carbenicillin in plasma or liver microsome preparations.
|
| Cell Assay |
Antibacterial activity is evaluated using standard broth microdilution assays against Gram-positive and Gram-negative bacterial strains. Minimum inhibitory concentrations (MICs) are determined after 18-24 hours of incubation at 37degC. The compound's activity is compared to that of carbenicillin to confirm prodrug conversion and efficacy.
|
| Animal Protocol |
Mouse protection models: Mice are infected with lethal doses of E. coli or S. aureus and treated orally with Carindacillin sodium at various doses. Survival rates, PD₅0 and PD₉₅ values are calculated. In urinary tract infection models, bacterial counts in urine and tissues are measured.
|
| ADME/Pharmacokinetics |
Carindacillin sodium has a molecular weight of 516.54 and a molecular formula of C2₆H2₅N2NaO₆S. It is an orally active prodrug that is hydrolyzed to carbenicillin in vivo. Oral administration achieves peak blood concentrations in 1-2 hours, and the drug is primarily excreted in urine.
|
| Toxicity/Toxicokinetics |
Adverse reactions are similar to those of carbenicillin and may include gastrointestinal disturbances, hypersensitivity reactions, and electrolyte imbalances. As a penicillin, it is contraindicated in patients with penicillin allergy. Carindacillin sodium is a prescription medication.
|
| References |
[1]. English AR, et, al. Carbenicillin indanyl sodium, an orally active derivative of carbenicillin. Antimicrob Agents Chemother. 1972 Mar;1(3):185-91.
[2]. Ries KM, et, al. Comparison of carbenicillin indanyl sodium, ampicillin, and cephaloglycin in treatment of urinary-tract infection. J Infect Dis. 1973 May;127:Suppl:148-53. |
| Additional Infomation |
Carlindacillin sodium is an organosodium salt containing a carlindacillin (1-) group. Cabenicillin-indanone sodium is the sodium salt of indanone-carbenicillin, a broad-spectrum semi-synthetic carboxypenicillin antibiotic with bactericidal activity. Cabenicillin acylates the C-terminal domain of penicillin-sensitive transpeptidase, causing the lactam ring of the antibiotic to open. This inactivation prevents the formation of peptidoglycan chain crosslinks, thereby inhibiting the third (and final) stage of bacterial cell wall synthesis. As a result, cell wall integrity is impaired, potentially leading to cell lysis. This drug is primarily used for Gram-negative bacterial infections and has limited antibacterial activity against Gram-positive bacteria.
Carindacillin sodium is an orally active prodrug of carbenicillin, a broad-spectrum penicillin antibiotic. It is used for the treatment of urinary tract infections. The drug is marketed by Pfizer as Geocillin. It is available as a prescription medication in some countries. |
| Molecular Formula |
C26H25N2NAO6S
|
|---|---|
| Molecular Weight |
516.54
|
| Exact Mass |
516.133
|
| CAS # |
26605-69-6
|
| PubChem CID |
23676503
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
812.5ºC at 760mmHg
|
| Melting Point |
207-213°
|
| Flash Point |
445.2ºC
|
| Vapour Pressure |
6.62E-28mmHg at 25°C
|
| LogP |
1.49
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
36
|
| Complexity |
894
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
[Na+].C1C=CC(C(C(N[C@@H]2C(=O)N3[C@H](C(S[C@H]23)(C)C)C([O-])=O)=O)C(OC2C=CC3CCCC=3C=2)=O)=CC=1
|
| InChi Key |
QFWPXOXWAUAYAB-XZVIDJSISA-M
|
| InChi Code |
InChI=1S/C26H26N2O6S.Na/c1-26(2)20(24(31)32)28-22(30)19(23(28)35-26)27-21(29)18(15-7-4-3-5-8-15)25(33)34-17-12-11-14-9-6-10-16(14)13-17;/h3-5,7-8,11-13,18-20,23H,6,9-10H2,1-2H3,(H,27,29)(H,31,32);/q;+1/p-1/t18?,19-,20+,23-;/m1./s1
|
| Chemical Name |
sodium;(2S,5R,6R)-6-[[3-(2,3-dihydro-1H-inden-5-yloxy)-3-oxo-2-phenylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 250 mg/mL (483.99 mM
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9360 mL | 9.6798 mL | 19.3596 mL | |
| 5 mM | 0.3872 mL | 1.9360 mL | 3.8719 mL | |
| 10 mM | 0.1936 mL | 0.9680 mL | 1.9360 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
